Johns Hop­kins sci­en­tists raise $137M megaround for a trio of spin­outs look­ing to tack­le Alzheimer’s, Parkin­son’s and fi­bro­sis

A US/Ko­re­an hy­brid biotech run by a group of sci­en­tists out of Johns Hop­kins just scored a megaround of $137.1 mil­lion, with plans to ad­vance a slate of ex­per­i­men­tal drugs held at its 3 sub­sidiary op­er­a­tions.

D&D Phar­mat­e­ch has a lead drug go­ing in­to Phase II at Neu­raly. The GLP-1R ag­o­nist NLY01 is be­ing stud­ied for Parkin­son’s and Alzheimer’s, look­ing to tamp down on neu­roin­flam­ma­tion. Johns Hop­kins’ Ted Daw­son — a pro­fes­sor of neu­rode­gen­er­a­tive dis­eases — runs that op­er­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER